[…] media spotlight last week after publication of their paper on the application of CRISPR technology in FSHD cells. In response to the public’s interest in the story, they prepared the following […]
Biology 101 for understanding the CRISPR research
Facioscapulohumeral muscular dystrophy community speaks to the FDA
The FSHD Society is holding a landmark meeting today in which individuals and families living with facioscapulohumeral muscular dystrophy (FSHD) will tell representatives from the U.S. Food and Drug Administration […]
Celebrating Moms
[…] approaching, we would like to take a moment to celebrate the amazing moms in the FSHD Community. Being a mother is learning about strengths you didn’t know you had, and […]
Genetic Cause
[…] two distinct genetic mechanisms. The most common, found in 95 percent or patients, is called FSHD Type 1, or FSHD1. The remaining 5 percent is called FSHD Type 2 (FSHD2), […]
DUX4 vs. PAX7–Who’s the fairest one of all?
[…] years, DUX4 has enjoyed center stage in the yet-unfolding story of facioscapulohumeral muscular dystrophy ( FSHD). DUX4 was first identified in 19991, but only in the past five to 10 […]